5 Ex-Dividend Stocks With Buy Ratings
NEW YORK ( TheStreet) -- The following stocks go ex-dividend Thursday, meaning an investor must purchase the shares Wednesday to qualify for the next dividend payment: Apache(APA) , CVS Caremark (CVS) , Hormel Foods (HRL) , Washington Post (WPO) and Weight Watchers (WTW) .
Each of the stocks received a buy rating from TheStreet Ratings .
The independent energy company is scheduled to report first-quarter results on May 3. Analysts, on average, anticipate earnings of $3.07 a share on revenue of $4.56 billion.
"APA continues to trade at the cheapest valuation in the large cap E&P sector despite signs the bear case in Egypt is not playing out," Credit Suisse analysts wrote in a March 27 report. "We believe this is a compelling entry point as its portfolio should deliver 8-10% production growth in 2012. We also expect strong growth in 2013 (7-9%) as more than 50% of this year's capex program is targeting longer-duration projects."
Forward Annual Dividend Yield: 0.7%
Rated "B (Buy)" by TheStreet Ratings : The company's fourth-quarter gross profit margin was about the same as it was the previous year.
Apache has weak liquidity. Its Quick Ratio is 0.68, which demonstrates a lack of ability to meet its short-term cash needs.
In the fourth quarter, stockholders' net worth increased 18.93% from the prior year.
TheStreet Ratings' price target is $109.61.
The drugstore chain is scheduled to report first-quarter results on May 2. Analysts, on average, expect earnings of 63 cents a share on revenue of $30.31 billion.
"Sales of lower priced generic drugs are expected to increase faster than those of branded drugs," Trefis analysts wrote in an April 4 report. "This growth will be supported by the fact that patents for a large number of branded drugs will expire soon (For example Pfizer's Lipitor drug with $11 billion in annual sales lost patent protection in Nov 2011). In 2011 alone, $50 billion worth of drugs would lose patent protection, opening them to generics and driving higher margins. Generics are cheaper than the costlier patent-protected drugs and hence shall drive lower Revenue per Retail prescription. In 2012, we expect the conversion to generic drugs will account for almost a 4% reduction in overall prescription revenues for CVS Caremark, leading to a decline in Revenue per Retail Revenue per Retail prescription."
Forward Annual Dividend Yield: 1.5%
Rated "A (Buy)" by TheStreet Ratings : The company's fourth-quarter gross profit margin decreased from the previous year.
CVS Caremark has weak liquidity. Its Quick Ratio is 0.62, which demonstrates a lack of ability to meet its short-term cash needs.